Breaking down PAD trials: who’s missing & what’s coming in 2025?

In this short expert video, Prof. Athanasios Saratzis reviews some of the most important recent randomised controlled trials (RCTs) in peripheral artery disease (PAD). 

He begins with the revealing RANDOM STOP study, which shows that 82 % of chronic limb-threatening ischemia (CLTI) patients seen in daily practice wouldn’t have met the inclusion criteria for any major Paclitaxel RCTs — underlining a significant research gap.

He then looks ahead to key UK vascular RCTs to watch in 2025, including EVOCC (open vs. endovascular treatment for aortoiliac disease), LEADER-PAD (Colchicine vs. placebo in PAD), and the HAMLET trial (below vs. above knee amputations).

Watch this 5-minute update to hear Prof. Saratzis share why these trials matter and how they could shape future PAD practice and patient outcomes.